François Vilcot,Carole-Anne Brugère,Jaime Fuentealba et al.
François Vilcot et al.
Over the past decade, ex vivo autologous chimeric antigen receptor (CAR)-T-cell therapies have reshaped the treatment of B-cell malignancies. Despite their remarkable clinical efficacy, their application remains limited by complex manufactu...
Chronic lymphocytic leukemia with IGH:: BCL3-translocation is characterized by a homogeneous and distinct genetic and epigenetic landscape [0.03%]
Cosima Drewes,Cristina López,Juan Emilio Martinez-Manjón et al.
Cosima Drewes et al.
Approximately 1% of chronic lymphocytic leukemia (CLL) cases harbor a translocation juxtaposing the immunoglobulin heavy chain (IGH) and B-cell lymphoma 3 (BCL3) loci. Aiming at comprehensive molecular characterization of IGH::BCL3-positive...
Correction to "Posttransplantation clonal dynamics of hematopoietic stem cells carrying prenatal and early-life DNMT3A mutations" [0.03%]
[This corrects the article DOI: 10.1002/hem3.70262.]. © 2026 The Author(s). HemaSphere published by John Wiley & Sons Ltd on behalf of European Hematolo...
Published Erratum
HemaSphere. 2026 Apr 28;10(4):e70365. DOI:10.1002/hem3.70365 2026
Galina Tsykunova,Eskild Bendix Kristiansen,Tor Henrik Anderson Tvedt et al.
Galina Tsykunova et al.
Rituximab is a well-established treatment for adult immune thrombocytopenia (ITP), with ~60% initial response (IR) and 20%-30% long-term remissions. We conducted a register-based cohort study of 759 ITP patients in Sweden, Denmark, and Norw...
A single JAK2-V617F hematopoietic stem cell can initiate myeloproliferative neoplasm when transplanted into non-conditioned recipient mice [0.03%]
Quentin Kimmerlin,Morgane Hilpert,Nils Hansen et al.
Quentin Kimmerlin et al.
Myeloproliferative neoplasms (MPNs) are clonal disorders of hematopoietic stem cells (HSCs) that are most frequently caused by acquired somatic mutations in JAK2. A number of conditional mouse models of JAK2-V617F-driven MPN have been gener...
Pharmacological inhibition of sclerostin protects bone from B-cell acute lymphoblastic leukemia-mediated destruction [0.03%]
Vincent Kuek,Joyce Oommen,Emanuela Ferrari et al.
Vincent Kuek et al.
Complement and transplant-associated thrombotic microangiopathy: Current and future approaches [0.03%]
Massimo Cugno,Francesco Onida,Bernhard Lämmle
Massimo Cugno
Moritz Reichert,Bethan Psaila
Moritz Reichert
Edeghonghon Olayemi
Edeghonghon Olayemi
Editorial
HemaSphere. 2026 Mar 31;10(4):e70311. DOI:10.1002/hem3.70311 2026
Nivolumab in combination with AVD as frontline treatment for patients with classic Hodgkin lymphoma: A real-world analysis from 20 US centers [0.03%]
Allison M Bock,Peirong Hao,Yizhe Xu et al.
Allison M Bock et al.